Topic

Florida

A collection of 504 issues

Myths vs. Facts: Getting Prolastin-C Covered by UnitedHealthcare in Florida (2025 Guide)

Answer Box: Prolastin-C Coverage by UnitedHealthcare in Florida UnitedHealthcare requires prior authorization for Prolastin-C with documented severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype), emphysema evidence, and step therapy trial of preferred alternatives like Aralast NP or Glassia unless contraindicated. Coverage falls under medical benefit with site-of-care preference for home infusion
6 min read

The Complete Requirements Checklist to Get Lamzede (velmanase alfa-tycv) Covered by Blue Cross Blue Shield in Florida

Answer Box: Getting Lamzede Covered by Blue Cross Blue Shield in Florida Who qualifies: Patients with confirmed alpha-mannosidosis (enzyme activity <10% normal + MAN2B1 genetic variants) experiencing non-CNS manifestations who can ambulate independently. Fastest path: Submit prior authorization through Florida Blue provider portal with: enzyme assay, genetic testing, specialist consultation,
7 min read

Myths vs. Facts: Getting Vigabatrin (Sabril) Covered by Cigna in Florida - Complete Appeals Guide

Answer Box: Getting Vigabatrin Covered by Cigna in Florida Fast Track to Approval: Cigna covers vigabatrin (Sabril, generics) for infantile spasms (ages 1 month-2 years) and refractory complex partial seizures (≥2 years) with prior authorization. Success requires: neurologist prescription, REMS enrollment, documented prior failures (for epilepsy), and vision monitoring plan.
6 min read

How to Get Pomalyst (Pomalidomide) Covered by UnitedHealthcare in Florida: Coding, Appeals, and REMS Requirements

Answer Box: Getting Pomalyst Covered by UnitedHealthcare in Florida UnitedHealthcare requires prior authorization for Pomalyst (pomalidomide) with specific documentation: C90.02 (multiple myeloma in relapse) ICD-10 code, proof of prior lenalidomide and proteasome inhibitor failure, and PS-Pomalidomide REMS enrollment. Submit via the UHC Provider Portal with pathology reports, treatment history,
6 min read